Education
About Us
Working with TipRanks
Follow Us
Kalaris Therapeutics (KLRS)
NASDAQ:KLRS
Total Valuation
Kalaris Therapeutics has a market cap or net worth of $40.00M. The enterprise value is -$52.15M.
Market Cap$40.00M
Enterprise Value-$52.15M
Share Statistics
Kalaris Therapeutics has 18,702,417 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,702,417
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Kalaris Therapeutics’s return on equity (ROE) is 0.33 and return on invested capital (ROIC) is 2210.84%.
Return on Equity (ROE)0.33
Return on Assets (ROA)-4.41
Return on Invested Capital (ROIC)2210.84%
Return on Capital Employed (ROCE)22.11
Revenue Per Employee0.00
Profits Per Employee-1.05M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio0.17
Price to Fair Value0.00
Price to FCF-4.08
Price to Operating Cash Flow-0.88
PEG Ratio―
Income Statement
In the last 12 months, Kalaris Therapeutics had revenue of 0.00 and earned -14.70M in profits. Earnings per share was -0.79.
Revenue0.00
Gross Profit0.00
Operating Income-13.46M
Pretax Income-14.70M
Net Income-14.70M
EBITDA-14.01M
Earnings Per Share (EPS)-0.79
Cash Flow
In the last 12 months, operating cash flow was -7.44M and capital expenditures 0.00, giving a free cash flow of -7.44M billion.
Operating Cash Flow-7.44M
Free Cash Flow-7.44M
Free Cash Flow per Share-0.40
Dividends & Yields
Kalaris Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.12
52-Week Price Change-86.30%
50-Day Moving Average2.87
200-Day Moving Average9.43
Relative Strength Index (RSI)36.87
Average Volume (3m)44.00K
Important Dates
Kalaris Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Kalaris Therapeutics as a current ratio of 0.85, with Debt / Equity ratio of 0.00%
Current Ratio0.85
Quick Ratio0.85
Debt to Market Cap0.00
Net Debt to EBITDA0.23
Interest Coverage Ratio-19.60
Taxes
In the past 12 months, Kalaris Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Kalaris Therapeutics EV to EBITDA ratio is 0.23, with an EV/FCF ratio of 0.22.
EV to Sales0.00
EV to EBITDA0.23
EV to Free Cash Flow0.22
EV to Operating Cash Flow0.22
Balance Sheet
Kalaris Therapeutics has $100.97M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$100.97M billion.
Cash & Marketable Securities$100.97M
Total Debt$0.00
Net Cash-$100.97M
Net Cash Per Share-$5.40
Tangible Book Value Per Share$0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Kalaris Therapeutics is $20.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$20.00
Price Target Upside736.82% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast72.12%